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Abstract
Background—The literature suggests a lack of consensus on the use of terms related to coeliac
disease (CD) and gluten.
Methods—A multi-disciplinary task force of 16 physicians from 7 countries used the electronic
database PubMed to review the literature with regards to CD-related terms up to January 2011.
Teams of physicians then suggested a definition for each term, followed by feedback of these
definitions through a web survey on definitions, discussions during a meeting in Oslo, and phone
conferences. We evaluated the following terms (in alphabetical order): Coeliac disease and the
following descriptors of CD: asymptomatic, atypical, classical, latent, non-classical, overt,
paediatric classical, potential, refractory, silent, subclinical, symptomatic, typical, CD serology,
CD autoimmunity, genetically at risk of CD, dermatitis herpetiformis, gluten, gluten ataxia, gluten
intolerance, gluten sensitivity, and gliadin-specific antibodies.
Results—CD was defined as “a chronic small intestinal immune-mediated enteropathy
precipitated by exposure to dietary gluten in genetically predisposed individuals”. Classical CD
was defined as “CD presenting with signs and symptoms of malabsorption. Diarrhoea,
steatorrhoea, weight loss or growth failure is required.” We suggest that “gluten-related disorders”
is the umbrella term for all diseases triggered by gluten and that the term gluten intolerance is not
to be used. Other definitions are presented in the paper.
Conclusion—This paper presents the Oslo definitions for CD-related terms.
Keywords
adult; autoimmunity; child; coeliac; gluten; sensitivity; intolerance
BACKGROUND
Coeliac disease (CD) is a chronic small intestinal immune-mediated enteropathy precipitated
by exposure to dietary gluten in genetically predisposed individuals. Although symptoms
and signs of CD have been recognised for more than 100 years, it was in the 1940s that the
Dutch paediatrician Dicke established a link between the protein component of wheat
(gluten) exposure and CD.1 CD and related diseases are now common chronic diseases in
children and adults, and increased diagnosis has lead to proliferation of research activities.
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As with many other chronic conditions, the boundaries of CD are not always clear, with the
consequence that there is considerable confusion and a lack of consensus regarding
diagnostic criteria of CD and related conditions.
The first consensus definition of CD was published in Acta Paediatrica in 1970.2 This
publication defined CD as a permanent condition of gluten intolerance with mucosal
flattening that (a) reversed on a gluten-free diet (GFD) and (b) then relapsed on re-
introduction of gluten. Although the definition of CD has undergone minor changes since
1970,3, 4 consensus definitions have been restricted to CD. However, the scientific
community has come to recognise that there is a spectrum of disorders related to gluten
ingestion.
Due to a lack of common definitions for the spectrum of terms and disorders related to CD,
a multi-disciplinary task force of 16 physicians from 7 countries with particular expertise in
diagnosis and treatment of CD proposes the following definitions for the variety of vague
and often confusing terms currently in use in the literature. These definitions are based on
thorough literature reviews (Table 1), a discussion in Oslo at the 14th International Coeliac
Disease Symposium in June 2011, and agreement on consensus statements by web survey
and phone conferences. We refer to our definitions as the “Oslo Definitions”.
The purpose of our recommended definitions is to create a foundation for both clinical
management and research. Clear definitions will allow for more efficient and generalizable
advances in CD research concerning aetiology, incidence, prevalence, complications, and
treatment of patients with CD and other gluten-related disorders.
METHODS
Task force constitution
Members of this collaborative effort were invited by DAL and CC. The constitution of the
group reflects the wide variety of disciplines to which CD may present in practice:
gastroenterology, histopathology, paediatrics, neurology, and dermatology. Members of the
task force originated from Sweden, US, Argentina, Italy, UK, Finland and Norway. Four of
the five physicians from the US had trained elsewhere (two in Ireland, one in Australia and
one in Italy).
Literature review
Teams of 3–4 physicians were assigned 1–4 CD-related terms. Each team first carried out a
literature search (Table 1). We searched the entire electronic database PubMed up to January
2011 using the terms of this review as key words. These included: Coeliac disease and these
descriptors of CD: asymptomatic, atypical, classical, latent, non-classical, overt, paediatric
classical, potential, refractory, silent, subclinical, symptomatic, typical, CD serology, CD
autoimmunity, genetically at risk of CD, dermatitis herpetiformis, gluten, gluten ataxia,
gluten intolerance, gluten sensitivity, and gliadin-specific antibodies.
We restricted most of our review to original papers and reviews. Most papers had been
published after 1990. The teams then suggested definitions for each term.
Web survey
We then constructed a web survey from which all suggested definitions were listed and
subjected to peer review (Appendix).
Comments and feedback from the web survey were taken into account when constructing a
second set of definitions.
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Discussions and phone meetings
The revised definitions and appending comments were then discussed in Oslo at the 14th
international CD symposium in June 2011. This discussion was followed by two phone
conferences in which the remaining definitions were discussed until consensus was
achieved. We did not grade the evidence underlying each definition because that was not the
purpose of our task force and this review did not deal with clinical management. For the
convenience of the readers, each definition is followed by a short literature review of each
term. Two terms were added after the initial web survey and the meeting in Oslo: Dermatitis
herpetiformis and CD autoimmunity were discussed through email.
RESULTS
Coeliac disease
A chronic small intestinal immune-mediated enteropathy precipitated by
exposure to dietary gluten in genetically predisposed individuals—CD is
triggered by the ingestion of gluten (definition below), the protein component of wheat, rye,
barley, but not oats.5, 6 Such exposure results in a variable degree of intestinal damage.7 In
most patients with CD, the enteropathy will reverse on a GFD.2–4 According to the
suggested definition, CD is a chronic disease, but as the discussion of the terms potential CD
and latent CD will show, there are reports of transient CD.8
Although CD is the most common cause of enteropathy in the western world and
enteropathy is a prerequisite for CD, it should be noted that other diseases may cause small
intestinal inflammation but do not qualify as CD.9 Typically, the inflammation in CD
includes an increased intraepithelial lymphocyte count, most often >25/100 cells.9, 10
Another feature of CD is that it incorporates an adaptive T-cell-mediated response (to
gluten) and that it occurs in DQ2-DQ8-positive individuals.11, 12 Increasingly, the presence
of specific endomysial antibodies (EMA, also called AEA), anti-tissue transglutaminase
antibodies (TTG, a-tTG, TTA), and/or deamidated antigliadin antibodies (DGP) plays an
important role in the serological work-up for CD. These antibodies strongly support the
diagnosis of CD, but by themselves are not confirmatory.
To confirm a diagnosis of CD biopsies of the duodenum must be taken when patients are on
a gluten-containing diet. Consensus states 4–6 biopsies are necessary for diagnosis,13
including from the duodenal bulb.14, 15
Three histological classifications of CD are used: Marsh,7 Marsh –Oberhuber16 and
Corazza10. A comparison of these classifications is shown in Table 2.
Historically, CD has been equivalent to sprue, coeliac sprue, gluten-sensitive enteropathy,
and gluten intolerance. In the past the terms non-tropical sprue and idiopathic steatorrhoea
were used.17, 18 None of these terms are currently recommended.
Gluten
Gluten is the commonly used term for the complex of water insoluble proteins
from wheat, rye and barley that are harmful to coeliac disease patients—The
major seed proteins in cereals are the alcohol soluble prolamins, a complex group of
alcohol-soluble polypeptides that make up about half of the protein in the mature grain. The
term gluten indicates a broad group of prolamins (gliadins and glutenins) found in wheat.
Other prolamins showing similar immunogenic properties are found also in rye (secalins),
barley (hordeins), and other closely related grains.13, 19 The major prolamins of the more
distantly related maize (zeins) seem to have evolved independently and show no harmful
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effects in coeliac patients. Oats also have been shown to be non-immunogenic in most
individuals with CD.20 A gluten-free diet usually indicates a diet free from wheat, rye,
barley, triticale, kamut and spelt.
Gluten is poorly digested in the human intestine with or without CD. Gluten peptides cross
intact into the submucosa of the small intestine. In the submucosa of the small intestine the
human enzyme transglutaminase 2 (TG2) also referred to as tissue transglutaminase (tTG)
deamidates gluten peptides, which allows for high-affinity binding to HLA DQ2 and HLA
DQ8 molecules, subsequently triggering an inflammatory reaction in patients with CD.12
Gluten-content in food is regulated by the Codex Alimentarius (http://
www.codexalimentarius.net). This codex (CODEX STAN 118 – 1979 revised in 2008)
states that gluten-free foods are those foods or ingredients naturally free of gluten, in which
the measured gluten level is ≤20 mg/kg in total, or processed to <100 mg/kg. By the current
Codex, foods meeting this criteria may be labelled as a ‘gluten-free food’.
Asymptomatic CD
CD not accompanied by symptoms even in response to direct questioning at
initial diagnosis—Individuals with asymptomatic CD do not manifest any symptoms
commonly associated with CD and have no symptoms that respond to gluten withdrawal,
even in response to direct questioning. These patients are often diagnosed through testing of
populations enrolled in screening programs or in case-finding strategies for detecting CD in
patients with disorders that are associated with a high risk for CD21–33 Many of these
patients suffer from decreased quality of life. Sometimes minor symptoms (e.g., fatigue) are
only recognized after the introduction of a GFD,34 such patients do not suffer from true
asymptomatic CD and should be re-classified as having subclinical CD.
Typical CD
Historically, typical CD has denoted a gluten-induced enteropathy presenting with signs or
symptoms of malabsorption/global malabsorption (such as diarrhoea or malnutrition) or a
malabsorption syndrome (indicated by weight loss, steatorrhoea, and oedema secondary to
hypoalbuminemia). The above use is questionable in that the clinical presentation of CD has
changed over time,35–37 and the word “typical” implies that this form is the most frequently
encountered form of CD. In contrast, many current patients have symptoms such as
anaemia,38–40 fatigue,41, 42 and abdominal pain43.
We therefore discourage the use of the term Typical CD.
Atypical CD
Atypical CD can only be used in reference to typical CD. Historically, atypical CD has been
used to describe patients with gluten-induced enteropathy that have no weight loss but
present with any of the following symptoms/signs: (a) gastrointestinal (GI) symptoms44
including symptoms suggestive of irritable bowel syndrome,45, 46 and liver
dysfunction47, 48; (b) extraintestinal manifestations, such as metabolic disease/symptoms
(failure to thrive, thyroid dysfunction (hypo/hyper)49, 50; (c) neurologic findings,51–53
including depression54 and gluten ataxia55; (d) reproductive disease56–58 including
abnormalities in menarche and menopause58, 59; (e) oral/cutaneous disease60–64 including
dermatitis herpetiformis (DH)65; and (f) skeletal findings66. Atypical CD has also been used
to denote patients with a gluten-induced enteropathy and significant nutritional deficiencies
(such as iron deficiency). We argue that the term atypical CD should not be used. Some
patients previously described as having atypical CD may fulfil the requirements for non-
classical CD (below).
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Classical CD
CD presenting with signs and symptoms of malabsorption. Diarrhoea,
steatorrhoea, weight loss or growth failure is required—Classical and typical CD
have traditionally been similar concepts defining the presence of a gluten-induced
enteropathy presenting with diarrhoea, malnutrition, or a malabsorption syndrome (indicated
by weight loss, steatorrhoea, and oedema secondary to hypoalbuminemia).7, 67–74 While
recognizing that these symptoms are not specific to CD, we encourage the use of classical
CD, as defined above, because the term “classical” does not imply that this type of CD is
more common than CD without clinical malabsorption. Examples of classical CD are
patients with diarrhoea and weight loss but also patients with weight loss and anaemia.
Paediatric classical CD is the paediatric equivalent of classical CD. These children are often
characterised by failure to thrive, diarrhoea, muscle wasting, poor appetite, and abdominal
distension.75–79 Many children with classical CD and malabsorption also show signs of
emotional distress (“change of mood”) and lethargy.72
Non-classical CD
CD presenting without signs and symptoms of malabsorption—In non-classical
CD the patient does not suffer from malabsorption (e.g., a patient with constipation and
abdominal pain but no malabsorption). Patients with monosymptomatic disease (other than
diarrhoea/steatorrhoea) usually suffer from non-classical CD.
Silent CD
Silent CD is equivalent to asymptomatic CD. We discourage the use of the term silent CD.
Subclinical CD
CD that is below the threshold of clinical detection—The term subclinical has often
been used to denote silent CD80–82 or CD patients with extraintestinal symptoms (and no GI
symptoms)83. The term has also been used for CD patients having clinical or laboratory
signs (iron deficiency anaemia, abnormalities in liver function tests, enamel defects,
incidental endoscopic features, osteoporosis, etc.) but no symptoms.84
As understanding of CD has advanced, new disease associations have been regularly found
and populations tested for CD have changed in response. For this reason what is
‘subclinical’ has changed over time. In order to provide a stable definition, we specified
subclinical CD to be disease that is below the threshold of clinical detection without signs or
symptoms sufficient to trigger CD testing in routine practice.
Symptomatic CD
CD characterized by clinically evident gastrointestinal and/or extraintestinal
symptoms attributable to gluten intake—The clinical manifestations of CD vary from
none (asymptomatic CD) to a wide spectrum of symptoms. The vast majority of authors
describing symptomatic CD do not distinguish between CD with GI and CD with
extraintestinal symptoms.85–98
What was previously called overt CD should be considered part of symptomatic CD.
Overt CD
Overt CD has most often been characterised by clinically evident gluten-related symptoms,
either GI (dyspepsia, diarrhoea, and bloating) or extraintestinal (neurological symptoms and
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fatigue).99, 100 We recommend that the term overt CD should not be used, and that
symptomatic CD is preferred.
Refractory CD
Persistent or recurrent malabsorptive symptoms and signs with villous
atrophy despite a strict gluten free diet for more than 12 months—Although
definitions of refractory CD (RCD) differ slightly,101–118 most expert opinion based
definitions include persistence or recurrence of malabsorptive symptoms and signs (e.g.,
diarrhoea, abdominal pain, involuntary loss of weight, low haemoglobin, and
hypoalbuminemia) associated with persistent or recurrent villous atrophy (VA) despite a
strict GFD for more than 12 months (or severe persistent symptoms independently of the
duration of GFD) in the absence of other causes of VA or malignant complications119 and
after the confirmation of the initial diagnosis of CD.
Generally, most patients have negative EMA and TTG antibodies at the time of RCD
diagnosis, but the presence of persisting elevated titres of circulating EMA and/or TTG
antibodies does not necessarily rule out RCD, though this should lead to questions about
dietary adherence. In all cases, a careful dietary interview should be performed to exclude
gluten exposure before diagnosing RCD.120 Not all dietary non-responsive CD is refractory
CD.121–123
RCD is divided into two categories:111, 115 type I, in which a normal intraepithelial
lymphocyte (IEL) phenotype is found, and type II, in which there is a clonal expansion of an
aberrant IEL population. The abnormal phenotype is supported by: loss of normal surface
markers CD3, CD4, and CD8 with preserved expression of intracytoplasmic CD3 (CD3ε) in
>50% of intraepithelial lymphocytes as evaluated by immunohistochemistry or >20% as
determined by flow cytometry, and by detection of clonal rearrangement of T-cell receptor
chains (γ or δ) by polymerase chain reaction.104, 107, 108, 115, 116
Latent CD
The literature reveals at least five definitions of latent CD: (1) Positive CD serology in
patients with normal mucosa or absence of VA124–129 and (2) normal mucosa in patients
who are on a gluten-containing diet, but have had an earlier or will have a later flat mucosa
when they eat gluten.130–134 To some physicians latent CD is (3) simply equivalent to
undiagnosed CD,135, 136 (4) whereas others refer to latent CD as CD preceded by another
autoimmune disease (e.g., type 1 diabetes or thyroid disease). Finally, (5) latent CD is
sometimes used to denote normal mucosa with non-serological abnormalities, such as an
increased number of gamma-delta cells or increased mucosal permeability.137 Considering
that the terms potential CD and latent CD have often been used interchangeably, resulting in
confusion, we discourage the use of latent CD.
Potential CD
Individuals with a normal small intestinal mucosa who are at increased risk of
developing CD as indicated by positive CD serology—Potential CD is also often
used with different meanings. For some, potential CD means that the patient has an
increased number of IELs in the villi138 or increased expression of gamma-delta cells.139 To
others potential CD describes individuals with normal mucosa but positive CD
serology.140, 141 Adding to this is the suggestion by Ferguson et al that all first-degree
relatives to patients with CD have potential CD.142
We recommend that the term potential CD be used for individuals with normal small
intestinal mucosa who are at increased risk of developing CD as indicated by positive CD
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serology. A difficulty in the definition of this group is variability in the adequacy of the
biopsies that were taken to exclude the diagnosis of active CD, especially with the current
knowledge that at least four biopsies need to be taken143 and the bulb may be the only
location of VA.15
Coeliac disease autoimmunity
Increased TTG or EMA on at least two occasions when status of the biopsy is
not known. If the biopsy is positive, then this is CD, if the biopsy is negative
than this is potential CD—The term “coeliac disease autoimmunity” or “coeliac
autoimmunity” has been used to describe: individuals with positive TTG144–147, positive
EMA148, positive EMA with positive/borderline TTG149, positive TTG on at least two
occasions150, and positive TTG on 2 occasions or a positive small bowel biopsy after only a
single positive TTG151.
We defined coeliac disease autoimmunity as positive TTG or EMA on at least two
occasions. In a clinical setting this will lead to a small intestinal biopsy, and patients can
then be classified as either CD (positive biopsy) or potential CD (negative biopsy), but in a
research setting there are circumstances where small intestinal biopsy has not been
performed. The term coeliac disease autoimmunity should then be used. When TTG or EMA
has only been tested on one occasion, it is preferable to refer to patients as TTG+ or EMA+.
Genetically at risk of CD
Family members of CD patients that test positive for HLA DQ2 and/or DQ8—
CD is a multi-factorial condition with unparalleled evidence of the pivotal role of human
leukocyte antigen (HLA)-DQA1*05-DQB1*02 (DQ2) and DQA1*03-DQB1*0302 (DQ8)
in disease predisposition.152, 153 Both DQ2 and DQ8 are major risk factors carried by almost
all CD patients. Interestingly, when carried in trans on DR5/DR7 (i.e. DQA1*05-
DQB1*0301/DQA1*0201-DQB1*02) or DR3/DR7 (i.e. DQA1*05-DQB1*02/DQA1*0201-
DQB1*02) genotypes, the risk of CD in Southern Europeans is higher than when the alleles
are carried in cis on DR3 (i.e. DQA1*05-DQB1*02) alone, suggesting that additional factors
in the region may be influencing disease propensity.
Non-HLA genes together contribute more to genetic susceptibility (approximately 65%)
than do the HLA genes (the remaining 35%), but the contribution from each single,
predisposing non-HLA gene appears to be modest.154
At the moment, the concept of genetically at risk for CD should be limited to family
members (of CD patients) who test positive for HLA-DQ2 or HLA-DQ8, with the
understanding that the risk varies between 2% and 20%, depending on the degree of the
relative with CD and the number of copies of HLA-DQ2 genes. However, any individual
who harbours these genes are at risk of developing CD.
Gluten intolerance
The term gluten intolerance has been used both as a synonym of CD and to indicate that a
patient experiences a clinical improvement after starting a GFD, even when he/she does not
have CD. 8, 76, 122, 155–166 However, we believe the term gluten intolerance is non specific
and carries inherent weaknesses and contradictions. Although gluten intolerance could be a
consequence of poor digestion, it could also be the effect of some lectin-like properties of
gluten or foods generated from gluten that cause GI upset. Another problem is that gluten
intolerance may not truly reflect intolerance to gluten but to other wheat components.156
Because of these contradictions, we recommend that the term gluten intolerance should not
be used and that gluten-related disorders be used instead.
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Gluten-related disorders
Gluten-related disorders is a term used to describe all conditions related to
gluten—We recommend that the term gluten-related disorders be used to describe all
conditions related to gluten. This may include such disorders as gluten ataxia, dermatitis
herpetiformis (DH), non-coeliac gluten sensitivity, and CD.115, 167, 168
Gluten sensitivity
In some papers the term gluten sensitivity is used synonymously with CD.7 Other papers
used the concept of gluten sensitivity as an umbrella term to include CD and other
conditions related to gluten ingestion, such as DH,169 gluten ataxia,170 and non-coeliac
gluten sensitivity.156 Most recently,157, 171–174 several authors employed the term gluten
sensitivity to describe a condition in which symptoms are triggered by gluten ingestion, in
the absence of TTG or EMA antibodies and enteropathy, with variable HLA status as well
as variable AGA presence. It is important to distinguish CD from less well characterized
diseases related to gluten ingestion. We therefore recommend that the term gluten sensitivity
should not be used and that non-coeliac gluten sensitivity be used instead.
Non-coeliac gluten sensitivity
One or more of a variety of immunological, morphological, or symptomatic
manifestations that are precipitated by the ingestion of gluten in individuals in
whom CD has been excluded—Non-coeliac gluten sensitivity (NCGS) is a condition in
which gluten ingestion leads to morphological or symptomatic manifestations despite the
absence of CD.172–176 As opposed to CD, NCGS may show signs of an activated innate
immune response but without the enteropathy, elevations in tTG, EMA or DGP antibodies,
and increased mucosal permeability characteristic of CD.173 Recently, Biesiekierski et al in
a double-blind randomized trial showed that patients with NCGS truly develop symptoms
when eating gluten.156 It is unclear at this time what components of grains trigger symptoms
in individuals with NCGS and whether some populations of NCGS patients have subtle
small intestinal morphological changes. While there currently is no standard diagnostic
approach to NCGS, systematic evaluation should be conducted including exclusion of CD
and other inflammatory disorders.
Gliadin-specific antibodies
Anti-gliadin (AGA) antibodies of both IgA and IgG subclass recognizing the
gliadin moiety of wheat. Antibodies recognizing native gluten are now rarely
used for diagnostic purposes because they lack general specificity.
Antibodies recognizing deamidated gliadin peptides demonstrate high
specificity and sensitivity. They can also be used for measurement of gluten
in food-stuffs—Use of the term gliadin specific antibodies generally refers to antibodies
directed against the gliadin moiety of wheat prolamins. Four aspects of these antibodies are
relevant to the spectrum of gluten-induced disease (I–IV).
(I) Diagnostic value. After introduction in the 1980s IgA antibodies against wheat gliadin
(AGA, anti-gliadin antibodies) served as the best serological test for CD for some
years.177, 178 However, its low positive predictive value179 meant that it has since been
abandoned for the investigation of CD,13, 179 outside of children below the age of 18
months, where IgA AGA seems to have high sensitivity.180 Recently assays for IgA and IgG
antibodies against deamidated gliadin peptides (DGP) have been introduced181 and perform
similarly to TTG-based tests.179 (II) Elevated levels of AGA have also been used for the
investigation of possible increased gut permeability but this use in clinical practice lacks a
strong scientific background. (III) AGAs are also relevant to gluten-induced disorders
Ludvigsson et al. Page 9
Gut. Author manuscript; available in PMC 2014 January 01.
$watermark-text
$watermark-text
$watermark-text
beyond the classical enteropathy. The most well-known example is that for gluten ataxia.
Patients with this disorder may have CD or only elevated levels of IgA or IgG AGAs.55 (See
Gluten Ataxia) (IV) Gluten-specific antibodies have a clear role in the food industry in that
they are indispensable for measurement of gluten in foods. More recently, an assay using a
monoclonal antibody recognising a major coeliac toxic epitope has been developed.182 This
assay is now the preferred method for gluten analysis in food.183
Coeliac disease serology
“Coeliac disease serology” is a term that includes endomysium,
transglutaminase, deamidated gliadin antibodies, and in small children also
gliadin antibodies for the assessment of CD—Since the introduction of AGA,
antibodies have become an important means to diagnose CD. Serological testing has been
used routinely in the investigation of CD since the 1980s. Whereas AGA tests were common
in the 1980s and 1990s,184 laboratories have since gradually shifted to EMA and TTG
tests.185–187 In most patient groups with suspected CD, EMA, and TTG tests have a higher
sensitivity and specificity than the AGA test.188 We defined CD serology as an all
encompassing term that includes all available tests which have been shown in clinical
studies to be sensitive for assessment of CD. Accordingly, we discourage the use of the term
CD serology in that it is preferable to specify the antibody tests used because sensitivity and
specificity differ substantially. We have nevertheless suggested a definition of this term,
since it is extensively used.
Gluten ataxia
Idiopathic sporadic ataxia and positive serum antigliadin antibodies even in
the absence of duodenal enteropathy—Gluten ataxia is one of a number of
neurological manifestations attributed to CD. Defining criteria for gluten ataxia170, 189, 190
include otherwise idiopathic sporadic ataxia in association with positive AGA with or
without enteropathy on duodenal biopsy. Most reports (22/35 reports) after 1998 have used
the same definition, i.e. idiopathic sporadic ataxia with positive AGA (IgG or IgA, or both).
However, a number of reports refer to patients with established CD (13/35 reports) without
always providing serological information on these patients other than stating that the patient
had CD (taken to imply the presence of enteropathy).170, 191–199
One report examined the presence of IgA deposits on duodenal biopsies and found that all
10 patients with gluten ataxia (without enteropathy) had such deposits.195 One study has
identified a novel transglutaminase (TTG6) as a potential new serological marker for gluten
ataxia,192 but currently the most appropriate definition for gluten ataxia remains that of
idiopathic sporadic ataxia with positive AGA.
Dermatitis herpetiformis (DH)
DH is a cutaneous manifestation of small intestinal immune-mediated
enteropathy precipitated by exposure to dietary gluten. It is characterized by
herpetiform clusters of pruritic urticated papules and vesicles on the skin,
especially on the elbows, buttocks, and knees, and IgA deposits in the dermal
papillae. DH responds to a GFD—DH is characterized by the presence of IgA deposits
in the skin200–202 DH is strongly linked to an immune mediated enteropathy precipitated by
gluten, 65, 203–205 and responds to a GFD.206–209 A study from the USA in 1992
documented a prevalence of 11.2 per 100,000 people and an incidence of 0.98 per 100,000
people per year,210 these rates are comparable to earlier studies of prevalence of DH in
Northern Europe. 205
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Villous atrophy will be revealed by a single intestinal biopsy in two thirds of patients, and
by multiple biopsies in 95%. The enteropathy is variable in severity, but even in the
presence of normal villous architecture, elevated levels of γδ T lymphocytes in the intestinal
mucosa, elevated intraepithelial lymphocyte counts and induction of villous atrophy are
noted on gluten challenge, and these patients are very likely to reflect the entire spectrum of
histological and clinical CD in adults.65, 211 The association with HLA is the same as in CD,
90% of patients have HLA DQ2 and, almost all the remainder, HLA DQ8.212 The skin
lesions clear with gluten withdrawal but may also require treatment by the neutrophil
inhibitor Dapsone. 207, 208, 213 In the long term, adherence to a strict GFD shows 47% of
patients can stop drug treatment completely; however 15% will not be able to reduce the
dose of Dapsone. 214
DISCUSSION
This review was done on the basis of PubMed literature searches and expert meetings. We
aimed to define key concepts relevant to CD and related disorders. The character of the
current paper implies that we did not pool any data or use any statistical tools. Instead, we
assembled an international team of recognized experts in CD research, discussed definitions
and tried to reach a consensus. This approach is similar to that of previous papers on
definitions in CD.2–4 As opposed to previous studies,2–4 however, we did not limit ourselves
to “CD only” but defined a large number of concepts. In addition, we give guidance to the
scientific and clinical community as to which terms should be used and which are to be
abandoned.
Overall, we evaluated more than 300 papers in detail and all authors participated in the
discussion leading to consensus definitions. We tried to avoid cumbersome definitions and
have mostly avoided the inclusion of specific techniques, antibodies, and measurements/
units in these definitions. Cumbersome definitions are rarely used in practice and because of
the progress in the CD research field, statements on specific tests may rapidly become
obsolete.
Our research team was multi-disciplinary and was composed of specialists from
gastroenterology, pathology, paediatrics, neurology, and dermatology. We hope that our
definitions will be acceptable to all specialties dealing with CD and gluten-related disorders
and anticipate that they will facilitate both research and clinical management of patients with
these disorders.
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SUMMARY BOX
What is already known about this subject
1. There is a lack of consensus on the use of terms related to coeliac disease and
gluten.
2. Variability in the use of terminology has led to difficulty when comparing and
evaluating clinical studies and research findings.
What are the new findings
1. The panel reached agreement regarding the definition of terms related to coeliac
disease and/or gluten currently in use in clinical practice and research.
2. Some terms in current use should be abandoned because they are outdated or
misleading.
How might it impact on clinical practice in the foreseeable future?
1. Uniform definitions for common terms relating to coeliac disease will improve
communication between researchers, clinicians, and the general public, and will
ensure that research is conducted and reported in a consistent manner.
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Table 1
Terms evaluated for this review.
Term PubMed hits until Jan 2011*
Defined
Coeliac disease (CD)# 14,843
Asymptomatic CD 39
Classical CD 10
Paediatric classical CD# -
Non-classical 3
Potential CD 33
Refractory CD 109
Subclinical CD 43
Symptomatic CD 26
CD autoimmunity§ 16
Genetically at risk of CD# -
Dermatitis Herpetiformis# 2759
Gluten# 8879
Gluten ataxia 28
Non-coeliac gluten sensitivity 85
Gliadin-specific antibodies† 5
Overt CD 10
Gluten related disorders 12
Discouraged
Atypical CD 13
Latent CD 78
Typical CD 11
Gluten intolerance 244
Gluten sensitivity 241
Silent CD 80
CD serology¶ 15
*We searched PubMed for the period Jan 1, 1900 to Jan 31, 2011. Individual co-authors then examined papers deemed most relevant. Where the
phrase “coeliac disease” is part of the definition, we searched PubMed for the relevant term and coeliac disease (British and American spelling).
For example, “silent coeliac disease”[All Fields] OR “silent coeliac disease”[All Fields] AND (“1900/01/01”[PDAT]: “2011/01/31”[PDAT])
#
For these terms, our literature review was entirely based on expert consensus of the literature because it was beyond the scope of this paper to
review all papers identified through PubMed (or as in the case of “paediatric classical CD” there were no hits).
§We searched both “Coeliac disease autoimmunity” and “coeliac autoimmunity” (both British and American spelling)
†A search for “gluten and antibodies” yielded 2,529 hits.
¶Although we discourage the use of “CD serology”, we have defined this term in the paper.
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Table 2
Comparison of histopathological classifications.
Morphology of duodenal mucosal
biopsy
Classification
Marsh* 7 Marsh-Oberhuber 16, 215 Corazza 10
Normal Type 0 Type 0 Normal
Normal architecture and increased
intraepithelial lymphocytes ≥25/100
enterocytes
Type 0 Type 0 Grade A
Normal architecture and increased
intraepithelial lymphocytes ≥ 40/100
enterocytes
Type 1 Type 1 Grade A
Normal architecture and increased
intraepithelial lymphocytes ≥ 40/100
enterocytes with crypt hyperplasia
Type 2 Type 2 Grade A
Partial villous atrophy and increased
intraepithelial lymphocytes ≥ 40/
≥25/100 enterocytes
Type 2 Hyperplastic
lesion Crypt hyperplasia,
increased crypt height
and influx of
inflammatory cells
Type 3 Destructive Grade B1 Atrophic,
villous to crypt ratio is
less than 3:1
Type 3a Partial villous atrophy; villi blunt
and shortened with a villous: crypt ratio,
1:1
Type 3b Subtotal villous atrophy; villi
atrophic but still separate and recognisable
Total villous atrophy intraepithelial
lymphocytes ≥ 40/≥25/100 enterocytes
Type 3 Destructive
Severe inflammation, flat
villi; hyperplastic crypts
Type 3c Total villous atrophy; villi
rudimentary or absent; mucosa resembles
colonic mucosa
Grade B2 Atrophic,
villi are no longer
detectable
Atrophic hypoplastic lesion: flat
mucosa, normal crypt height, no
inflammation with normal
intraepithelial lymphocyte counts
No equivalent Type 4 No equivalent
*
Marsh initially explored the association of mucosal damage with a progressively increased gluten intake in treated CD patients. This staging has
since been used as a classification.
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